Owing to various reasons, the demand for cell therapies is anticipated to increase over the coming years. Therefore, both therapy developers and contract service providers may need to strengthen their capabilities and expand available capacity. In this context, automation is expected to be a key enabler within the cell therapy manufacturing and contract services industry
To order this 550+ page report, which features 160+ figures and 250+ tables, please
Owing to benefits, such as reduced manufacturing costs, availability of cheap and skilled labor, and a supportive regulatory landscape, biopharmaceutical developers from across the globe, are increasingly outsourcing their manufacturing operations to China based CMOs. Further, in order to meet the growing demand for their services, Chinese CMOs are actively consolidating / expanding their capabilities through partnerships and / or dedicated expansion initiatives.
The “Cell and Advanced Therapies Supply Chain Management Market, 2020-2030” report features an extensive study of the innovative software solutions that are being used to improve / optimize various supply chain-related processes of cell and advanced therapies. Read more
Manufacturing cell therapies is technically and financially demanding; as a result, despite therapy developers gradually strengthening their in-house expertise, they are also becoming increasingly reliant on contract service providers
Roots Analysis is pleased to announce the publication of its recent study, titled, “
To order this 550+ page report, please visit this link
Key Inclusions
A detailed review of the overall landscape of companies that are engaged in the manufacturing of cell-based therapies, including information on the type of cells manufactured (including immune cells (including T cells,
To order this detailed 250+ page report, please visit this link
Key Inclusions
A detailed review of the overall landscape of companies offering contract manufacturing services for biopharmaceuticals in China, along with information on year of establishment, company size, scale
Various service providers claim to possess the required equipment for API synthesis under hazardous (high / low temperature and high / low pressure) conditions. Over time, the shift to high energy synthesis chemistries has demonstrated the benefits of closed, continuous reaction processes. Although many players continue to prefer the standard batch process, many are gradually adopting continuous flow technologies, especially for hazardous reactions.
Human factors engineering and usability testing have now become an essential part of product design across almost all industries, offering developers the chance to optimize proprietary products in alignment to the preferences of consumers
To order this 200+ page report, which features 120+ figures and 100+ tables, please visit this
Given the complex R&D protocols and the increasing demand for clinical evidence of therapeutic benefit, there seems to be a lucrative opportunity for contract research providers engaged in the medical devices’ domain. In fact, since 2000, 150 new CROs have been established that offer a variety of cost-efficient services and solutions to medical device developers.
To order this 400+ page report, which features 240+ figures and 200+ tables, please visit this ... Read more
Given the invasive and cost-intensive nature of tissue biopsies, there is a significant unmet need for safer and more patient-friendly cancer diagnostics that are capable of offering highly accurate, and actionable insights related to the disease.
To order this 350+ page report, which features 150+ figures and 200+ tables, please visit thislink ... Read more
To order this detailed 300+ page report, please visit this link
Key Inclusions
A detailed review of the overall landscape of companies offering contract services for manufacturing of microbiome therapeutics, including information on year of establishment, company size, scale of operation (preclinical
Over the years outsourcing has become a popular trend among medical device developers, allowing such companies to leverage the expertise / substantial production capabilities of CMOs / CDMOs in order to gain cost and time related benefits
Roots Analysis is pleased to announce the publication of its recent study, titled, “
To order this detailed 400+ page report, please visit thislink
Key Inclusions
A detailed review of the overall landscape of medical device CROs, along with information on year of establishment, company size, location of headquarters, type of service offered by [A]
Liquid biopsies have emerged as a versatile diagnostic solution, especially for cases when conventional (invasive) diagnostic tests are inconclusive or when the clinical condition is related to an organ that is not amenable to biopsy access
Roots Analysis is pleased to announce the publication of its recent study, titled, “ ... Read more
To order this 350+ page report, please visit this link
Key Inclusions
A detailed review of the overall landscape of the non-invasive cancer diagnostics market, featuring information on the developers of such products and analyses based on a number of relevant
Manufacturing live biotherapeutic products is both technically challenging and financially demanding; as a result, innovator firms are becoming increasingly reliant on contract service providers to access specialized facilities and optimize overall costs.
To order this 300+ page report, which features 140+ figures and 125+ tables, please visit this
To order this detailed 590+ page report, please visit this link
Key Inclusions
A detailed review of the overall landscape of the medical device contract manufacturing market, featuring a list of CMOs engaged in this domain, and detailed analysis based on a number of relevant
Advances in the medical device industry have led to a substantial increase in developmental complexity, clinical trial conduct, and stringency of regulatory review, causing sponsors to rely on the technical and regulatory affairs management expertise of CROs
Roots Analysis is pleased to announce the publication of its recent study, titled, “
More than 100 medical devices were approved by the FDA in 2018, while several are currently being evaluated across more than 9,500 (active) clinical trials, worldwide. Further, increase in aging population, coupled with rise in the prevalence of chronic disorders, are likely to drive the demand for medical devices. Therefore, in order to reduce the overall cost and expedite the time to market, majority of original equipment manufacturers (OEMs) are outsourcing their medical device ... Read more
Manufacturing live biotherapeutic product is both technically challenging and financially demanding; as a result, innovator firms are becoming increasingly reliant on contract service providers to access specialized facilities and optimize overall costs.
Roots Analysis is pleased to announce the publication of its recent study, titled, “
